 Valsartan
"Valsartan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.
| Descriptor ID |
D000068756
|
| MeSH Number(s) |
D03.383.129.617.850 D12.125.070.950.550 D12.125.142.930.500
|
| Concept/Terms |
Valsartan- Valsartan
- N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
|
Below are MeSH descriptors whose meaning is more general than "Valsartan".
Below are MeSH descriptors whose meaning is more specific than "Valsartan".
This graph shows the total number of publications written about "Valsartan" by people in this website by year, and whether "Valsartan" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 2 | 2 | | 2008 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2019 | 1 | 2 | 3 | | 2020 | 2 | 0 | 2 | | 2021 | 2 | 2 | 4 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Valsartan" by people in Profiles.
-
Vissing CR, Axelsson Raja A, Day SM, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Bundgaard H, Orav EJ, Ho CY. Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial. JAMA Cardiol. 2023 11 01; 8(11):1083-1088.
-
Page RL. The Real-World Price of Switching to?an?ARNI: A Case for De Novo Sacubitril/Valsartan Initiation. J Am Coll Cardiol. 2023 01 31; 81(4):332-335.
-
Pierce JB, Li Z, Greiner MA, Lippmann SJ, Hardy NC, Shen X, Stampehl M, Mentz RJ, Allen LA, Peterson PN, Fonarow GC, O'Brien EC, Greene SJ. Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry. Circ Heart Fail. 2023 01; 16(1):e010176.
-
Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Vargas JD, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL, Burns KM, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021 10; 27(10):1818-1824.
-
Carnicelli AP, Li Z, Greiner MA, Lippmann SJ, Greene SJ, Mentz RJ, Hardy NC, Blumer V, Shen X, Yancy CW, Peterson PN, Allen LA, Fonarow GC, O'Brien EC. Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart?Failure With Reduced Ejection Fraction. JACC Heart Fail. 2021 12; 9(12):876-886.
-
Greene SJ, Choi S, Lippmann SJ, Mentz RJ, Greiner MA, Hardy NC, Hammill BG, Luo N, Samsky MD, Heidenreich PA, Laskey WK, Yancy CW, Peterson PN, Curtis LH, Hernandez AF, Fonarow GC, O'Brien EC. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. J Am Heart Assoc. 2021 08 17; 10(16):e021459.
-
Carnicelli AP, Lippmann SJ, Greene SJ, Mentz RJ, Greiner MA, Hardy NC, Hammill BG, Shen X, Yancy CW, Peterson PN, Allen LA, Fonarow GC, O'Brien EC. Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. J Card Fail. 2021 08; 27(8):826-836.
-
Dickert NW, Mitchell AR, Venechuk GE, Matlock DD, Moore MA, Morris AA, Pierce KJ, Speight CD, Allen LA. Show Me the Money: Patients' Perspectives on a Decision Aid for Sacubitril/Valsartan Addressing Out-of-Pocket Cost. Circ Cardiovasc Qual Outcomes. 2020 12; 13(12):e007070.
-
Venechuk GE, Allen LA, Doermann Byrd K, Dickert N, Matlock DD. Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan. Circ Cardiovasc Qual Outcomes. 2020 09; 13(9):e006255.
-
Shirazi FM, Banerji S, Nakhaee S, Mehrpour O. Effect of angiotensin II blockers on the prognosis of COVID-19: a toxicological view. Eur J Clin Microbiol Infect Dis. 2020 Oct; 39(10):2001-2002.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|